Compass Pathways Plc Overview
Industry: Medical Care Facilities
Sector: Healthcare
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Compass Pathways Plc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Compass Pathways Plc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Compass Pathways Plc Competitors
Compass Pathways Plc operates in the Medical Care Facilities industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans